Lupin gets USFDA nod to market HIV drug in the US market

Drug major Lupin today said it has received US health regulator's approval to market

RELATED ARTICLES

generic version of ViiV Healthcare's Trizivir tablets, used in the treatment of HIV-1 infection, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement.

The company's product is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection, it added.

"Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Trizivir tablets and as such will be entitled to 180 days of marketing exclusivity," the company said.

According to IMS MAT September 2013 sales data, Trizivir tablets has US sales of around $111.6 million.

Lupin's cumulative ANDA filings with the USFDA as of October 30 stands at 183 and the Mumbai-headquartered firm has received 93 approvals to date.

During the current year, the company has so far received 17 approvals from USFDA. It has also launched 13 products in the US market in the current year so far.

"Lupin is the market leader in 26 products in the US generic market and is amongst the top three by market share in 40 products out of the overall 57 products in the market," it the company said.

Shares of Lupin were trading at Rs 863.70 a piece on the BSE in afternoon trade, up 1.28% from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The economic survey falls in step with the BJP’s election manifesto

    It’s always tough to find something wrong with the annual economic survey as it only articulates the government’s desire to set its house in order

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Why higher education needs innovation

India is such a great country that it creates complexity ...

Zehra Naqvi

We must overcome the fear of death

It is the biggest irony that the only thing that’s ...

Dharmendra Khandal

Jawai leopards and locals can coexist peacefully

At first glance, the Jawai landscape seems like a large ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture